Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court ...

Insurance giant Cigna accused Bristol Myers Squibb (BMS) of maintaining a monopoly over Pomalyst (pomalidomide), the pharma company’s $2-billion-a-year immunomodulatory drug for multiple myeloma. In a ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it ...

Cigna (CI) sues Bristol Myers Squibb (BMY), over antitrust violations related to marketing of its multiple myeloma drug, Pomalyst. Read more here.

Cigna Group (CI) filed a lawsuit against Bristol Myers Squibb (BMY), accusing the pharmaceutical gia PREMIUM Upgrade to read this MT Newswires article and get so much more.

Cigna, based in Bloomfield, Connecticut, is seeking unspecified triple damages from Princeton, New Jersey-based Bristol Myers Squibb. Bristol Myers Squibb has not yet responded to requests for comment ...